Takeaway

• The incidence of metastatic prostate cancer at diagnosis has increased as PSA screenings decreased across US states.
• States with larger declines in PSA screening have larger increases in the incidence of metastatic disease at diagnosis. 

Why this matters

• The authors support shared decision-making policies recommended in the 2018 United States Preventive Services...